Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2686923 | 1.00 | TP53 (0.32) | TP53 | |
| SCHEMBL840126 | 1.00 | TP53 (0.32) | TP53 | |
| SCHEMBL1369677 | 0.82 | — | — | |
| SCHEMBL13413224 | 0.82 | — | — | |
| SCHEMBL13413222 | 0.82 | — | — | |
| SCHEMBL25176906 | 0.80 | APLNR (0.31) | — | |
| SCHEMBL19260399 | 0.80 | — | — | |
| SCHEMBL15717701 | 0.80 | APLNR (0.31) | — | |
| SCHEMBL8221420 | 0.80 | APLNR (0.31) | — | |
| SCHEMBL8823309 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304523-A1 | COMBINED LACTATE AND KETONE BODY ESTERS FOR MEDICAL AND NUTRITIONAL USE | AARHUS UNIVERSITET (DK) | 2025-10-02 | — | — | US | disclosed |
| EP-4583867-A2 | SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | Latigo Biotherapeutics, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| US-20250154109-A1 | SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | LATIGO BIOTHERAPEUTICS, INC | 2025-05-15 | — | — | US | disclosed |
| CN-119894509-A | Sodium channel blocking compounds, derivatives thereof, and methods of use thereof | 拉堤果生物医疗股份有限公司 | 2025-04-25 | — | — | CN | disclosed |
| EP-4519239-A1 | COMBINED LACTATE AND KETONE BODY ESTERS FOR MEDICAL AND NUTRITIONAL USE | Aarhus Universitet (DK) | 2025-03-12 | — | — | EP | disclosed |
| WO-2025029890-A1 | SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | LATIGO BIOTHERAPEUTICS, INC. (US) | 2025-02-06 | — | — | WO | disclosed |
| CN-119212974-A | Combination lactic acid and ketoesters for medical and nutritional use | 奥胡斯大学 | 2024-12-27 | — | — | CN | disclosed |
| EP-4472966-A2 | SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | Latigo Biotherapeutics, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| US-20240139158-A1 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | PROTEOSTASIS THERAPEUTICS INC (US) | 2024-05-02 | — | — | US | disclosed |
| US-20240116878-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2024-04-11 | — | — | US | disclosed |
| US-8168648-B2 | Camptothecin derivatives and uses thereof | TAIWAN LIPOSOME CO., LTD. (TW) | 2012-05-01 | — | — | US | disclosed |
| US-20100227877-A1 | NEW CAMPTOTHECIN DERIVATIVES AND USES THEREOF | TAIWAN LIPOSOME CO. LTD. (TW) | 2010-09-09 | — | — | US | disclosed |
| US-20100227877-A1 | NEW CAMPTOTHECIN DERIVATIVES AND USES THEREOF | TAIWAN LIPOSOME CO. LTD. (TW) | 2010-09-09 | — | — | US | disclosed |
| US-7582781-B2 | epoxidation to produce 1,2-Epoxy-2-(2,4-difluorophenyl)butan-3-ol intermediate for pharmaceutical drugs, a triazole antifungal agent | KANEKA CORPORATION (JP) | 2009-09-01 | — | — | US | disclosed |
| EP-1475370-B1 | OPTICALLY ACTIVE AZOLE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | MITSUI CHEMICALS INC (JP) | 2009-08-05 | — | — | EP | disclosed |
| US-7271185-B2 | Optically active azole derivative and process for producing the same | MITSUI CHEMICALS, INC. (JP) | 2007-09-18 | — | — | US | disclosed |
| US-20060155136-A1 | Optically active halohydrin derivative and process for producing optically active epoxy alcohol derivative from the same | KANEKA CORPORATION (JP) | 2006-07-13 | — | — | US | disclosed |
| EP-1647551-A1 | OPTICALLY ACTIVE HALOHYDRIN DERIVATIVE AND PROCESS FOR PRODUCING OPTICALLY ACTIVE EPOXY ALCOHOL DERIVATIVE FROM THE SAME | KANEKA CORPORATION (JP) | 2006-04-19 | — | — | EP | disclosed |
| US-20050085521-A1 | Optically active azole derivative and process for producing the same | MITSUI CHEMICALS, INC. (JP) | 2005-04-21 | — | — | US | disclosed |
| EP-1475370-A1 | OPTICALLY ACTIVE AZOLE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | Mitsui Chemicals, Inc. (JP) | 2004-11-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154109-A1 | SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | SCN8A, TRPV1, SCNN1A | TP53 4831/4885 |
| US-20060155136-A1 | Optically active halohydrin derivative and process for producing optically active epoxy alcohol derivative from the same | TALDO1, CYP51A1, ERG28 | TP53 4710/4885 |
| US-20050085521-A1 | Optically active azole derivative and process for producing the same | ADH1C, ADH1A, ADH5 | TP53 4538/4885 |
| US-20240116878-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | PTPN5, PTPN2, PTPN22 | TP53 241/4885 |
| US-20250304523-A1 | COMBINED LACTATE AND KETONE BODY ESTERS FOR MEDICAL AND NUTRITIONAL USE | LDHB, LDHA, LCT | TP53 1240/4885 |
| US-20240139158-A1 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | SMPD1, ELANE, SMPD2 | TP53 4251/4885 |
| US-20100227877-A1 | NEW CAMPTOTHECIN DERIVATIVES AND USES THEREOF | LDHA, LDHB, TOP2A | TP53 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.